139 related articles for article (PubMed ID: 20850841)
1. Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma.
Ishimaru T; Lau J; Jackson AL; Modiano JF; Weiss RH
J Urol; 2010 Nov; 184(5):2143-9. PubMed ID: 20850841
[TBL] [Abstract][Full Text] [Related]
2. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382.
Ljungman M; Paulsen MT
Mol Pharmacol; 2001 Oct; 60(4):785-9. PubMed ID: 11562441
[TBL] [Abstract][Full Text] [Related]
3. Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53.
Park SH; Park JY; Weiss RH
J Urol; 2008 Jul; 180(1):352-60. PubMed ID: 18499163
[TBL] [Abstract][Full Text] [Related]
4. Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53.
Slovackova J; Smarda J; Smardova J
Neoplasma; 2012; 59(6):606-12. PubMed ID: 22862161
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors.
Atienza C; Elliott MJ; Dong YB; Yang HL; Stilwell A; Liu TJ; McMasters KM
Int J Mol Med; 2000 Jul; 6(1):55-63. PubMed ID: 10851267
[TBL] [Abstract][Full Text] [Related]
6. Common and reversible regulation of wild-type p53 function and of ribosomal biogenesis by protein kinases in human cells.
David-Pfeuty T; Nouvian-Dooghe Y; Sirri V; Roussel P; Hernandez-Verdun D
Oncogene; 2001 Sep; 20(42):5951-63. PubMed ID: 11593402
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.
Hahntow IN; Schneller F; Oelsner M; Weick K; Ringshausen I; Fend F; Peschel C; Decker T
Leukemia; 2004 Apr; 18(4):747-55. PubMed ID: 14973497
[TBL] [Abstract][Full Text] [Related]
8. Effects of the cyclin-dependent kinase inhibitor R-roscovitine on eosinophil survival and clearance.
Farahi N; Uller L; Juss JK; Langton AJ; Cowburn AS; Gibson A; Foster MR; Farrow SN; Marco-Casanova P; Sobolewski A; Condliffe AM; Chilvers ER
Clin Exp Allergy; 2011 May; 41(5):673-87. PubMed ID: 21255143
[TBL] [Abstract][Full Text] [Related]
9. Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
Paprskárová M; Krystof V; Jorda R; Dzubák P; Hajdúch M; Wesierska-Gadek J; Strnad M
J Cell Biochem; 2009 Jun; 107(3):428-37. PubMed ID: 19308936
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of polyamine oxidase prevented cyclin-dependent kinase inhibitor-induced apoptosis in HCT 116 colon carcinoma cells.
Gürkan AC; Arisan ED; Obakan P; Palavan-Ünsal N
Apoptosis; 2013 Dec; 18(12):1536-47. PubMed ID: 23892915
[TBL] [Abstract][Full Text] [Related]
11. Roscovitine inhibits extrusion of second polar body and induces apoptosis in rat eggs cultured in vitro.
Tripathi A; Chaube SK
Pharmacol Rep; 2015 Oct; 67(5):866-74. PubMed ID: 26398378
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
13. Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells.
Wesierska-Gadek J; Schmitz ML; Ranftler C
J Cell Biochem; 2007 Mar; 100(4):865-74. PubMed ID: 17203463
[TBL] [Abstract][Full Text] [Related]
14. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells.
Mohapatra S; Chu B; Zhao X; Pledger WJ
Cancer Res; 2005 Sep; 65(17):7717-23. PubMed ID: 16140939
[TBL] [Abstract][Full Text] [Related]
15. The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.
Ferguson M; Luciani MG; Finlan L; Rankin EM; Ibbotson S; Fersht A; Hupp TR
Cell Cycle; 2004 Jan; 3(1):80-9. PubMed ID: 14657672
[TBL] [Abstract][Full Text] [Related]
16. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.
Alvi AJ; Austen B; Weston VJ; Fegan C; MacCallum D; Gianella-Borradori A; Lane DP; Hubank M; Powell JE; Wei W; Taylor AM; Moss PA; Stankovic T
Blood; 2005 Jun; 105(11):4484-91. PubMed ID: 15692065
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
18. Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases.
Kotala V; Uldrijan S; Horky M; Trbusek M; Strnad M; Vojtesek B
Cell Mol Life Sci; 2001 Aug; 58(9):1333-9. PubMed ID: 11577989
[TBL] [Abstract][Full Text] [Related]
19. Human embryonic stem cells display a pronounced sensitivity to the cyclin dependent kinase inhibitor Roscovitine.
Videla-Richardson GA; Furmento VA; Garcia CP; Morris-Hanon O; Sevlever GE; Romorini L; Scassa ME
BMC Mol Cell Biol; 2019 Aug; 20(1):40. PubMed ID: 31462218
[TBL] [Abstract][Full Text] [Related]
20. Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.
Wesierska-Gadek J; Borza A; Komina O; Maurer M
Acta Biochim Pol; 2009; 56(3):495-501. PubMed ID: 19724778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
